Joanne Lundy

536 total citations
24 papers, 377 citations indexed

About

Joanne Lundy is a scholar working on Oncology, Immunology and Cancer Research. According to data from OpenAlex, Joanne Lundy has authored 24 papers receiving a total of 377 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 9 papers in Immunology and 6 papers in Cancer Research. Recurrent topics in Joanne Lundy's work include Pancreatic and Hepatic Oncology Research (12 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Cancer Genomics and Diagnostics (6 papers). Joanne Lundy is often cited by papers focused on Pancreatic and Hepatic Oncology Research (12 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Cancer Genomics and Diagnostics (6 papers). Joanne Lundy collaborates with scholars based in Australia, United States and China. Joanne Lundy's co-authors include Daniel Croagh, Brendan J. Jenkins, Ben Markman, Bo Gao, Michael Millward, Linda Mileshkin, Michael Friedländer, Virginia Paton, Tarek Meniawy and Alison Freimund and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Oncogene.

In The Last Decade

Joanne Lundy

23 papers receiving 374 citations

Peers

Countries citing papers authored by Joanne Lundy

Since Specialization

Citations

This map shows the geographic impact of Joanne Lundy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joanne Lundy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joanne Lundy more than expected).

Fields of papers citing papers by Joanne Lundy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joanne Lundy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joanne Lundy. The network helps show where Joanne Lundy may publish in the future.

Co-authorship network of co-authors of Joanne Lundy

This figure shows the co-authorship network connecting the top 25 collaborators of Joanne Lundy. A scholar is included among the top collaborators of Joanne Lundy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joanne Lundy. Joanne Lundy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01.	Journal of Clinical Oncology	Janine Lombard, Joanne Lundy et al.	2
2	Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: Update from the LOXO-RAS-20001 trial.	Journal of Clinical Oncology	Konstantin H. Dragnev, Yonina R. Murciano‐Goroff et al.	0
3	A Humanized Patient-Derived Xenograft Model for Pancreatic Cancer	Methods in molecular biology	Joanne Lundy	1
4	997MO A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors: STAMINA-01	Annals of Oncology	Ganessan Kichenadasse, Janine Lombard et al.	1
5	Endoscopic Ultrasound-Guided Fine-Needle Biopsies to Generate Preclinical Disease Models to Study Inflammation in Pancreatic Ductal Adenocarcinoma	Methods in molecular biology	Joanne Lundy, Daniel Croagh	1
6	700P First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors	Annals of Oncology	Adam Cooper, Vladimir Andelkovic et al.	2
7	Relationship between circulating tumour DNA and skeletal muscle stores at diagnosis of pancreatic ductal adenocarcinoma: a cross-sectional study	Scientific Reports	Catherine E. Huggins, Joanne Lundy et al.	6
8	Circulating Tumor DNA Is an Accurate Diagnostic Tool and Strong Prognostic Marker in Pancreatic Cancer	Pancreas	Samar Masoumi Moghaddam, Joanne Lundy et al.	2
9	KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation?	Cells	Joanne Lundy, Andrew Strickland et al.	25
10	Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors.	Journal of Clinical Oncology	Gonzalo Tapia, Joanne Lundy et al.	2
11	Blockade of the protease ADAM17 ameliorates experimental pancreatitis	Proceedings of the National Academy of Sciences	Mohamed I. Saad, Joanne Lundy et al.	16
12	Targeted Transcriptome and KRAS Mutation Analysis Improve the Diagnostic Performance of EUS-FNA Biopsies in Pancreatic Cancer	Clinical Cancer Research	Joanne Lundy, Hugh Gao et al.	7
13	EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy	Frontiers in Oncology	Joanne Lundy, Marion Harris et al.	5
14	TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma	Oncogene	Joanne Lundy, Linden J. Gearing et al.	14
15	High circulating tumour DNA is a strong negative prognostic factor in operable pancreatic cancer	HPB	Joanne Lundy, Daniel Croagh et al.	3
16	Interim data: Phase I/IIa study of EGFR-targeted EDV nanocells carrying cytotoxic drug PNU-159682 (E-EDV-D682) with immunomodulatory adjuvant EDVs carrying α-galactosyl ceramide (EDV-GC) in patients with recurrent, metastatic pancreatic cancer.	Journal of Clinical Oncology	Joanne Lundy, Gavin Marx et al.	3
17	Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial	The Lancet Oncology	Michael Friedländer, Tarek Meniawy et al.	89
18	An Organoid/Immune Cell Co‐Culture as a Predictive Model for the Treatment of Pancreatic Cancer	The FASEB Journal	Jayati Chakrabarti, Joanne Lundy et al.	2
19	A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.	Journal of Clinical Oncology	Michael Friedländer, Tarek Meniawy et al.	25
20	Pulmonary metastases, a potential biologic consequence of anesthetic-induced immunosuppression by thiopental.	PubMed	Joanne Lundy, Philip B. Conran et al.	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact